News & Updates

Antibiotic Novobiocin found to kill tumor cells with DNA-repair glitch

06/24/2021

Excerpt from the Article: An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows. The findings have spurred investigators to open a clinical trial of the drug, novobiocin, for patients whose tumors carry the abnormality. In…

Read More

CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity

06/23/2021

Excerpt from the Press Release: STUDY SHOWS GUARDANT REVEAL™ BLOOD-ONLY LIQUID BIOPSY TEST PREDICTS RISK FOR COLORECTAL CANCER RECURRENCE WITH INDUSTRY-LEADING SENSITIVITY For patients with early-stage colorectal cancer (CRC), the presence of circulating tumor DNA (ctDNA) or minimal residual disease (MRD) after curative intent treatment is becoming an important prognostic biomarker for cancer recurrence, and can…

Read More

Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

06/23/2021

Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, June 17, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the first patient has been dosed in a Phase II basket trial of taletrectinib…

Read More

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

06/22/2021

Excerpt from the Press Release: TEL AVIV, Israel and BETHESDA, Maryland, June 17, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases. The announcement of the new research projects…

Read More

CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research

06/22/2021

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that results from its Phase 1 first-in-human study of CX-2029 in patients with advanced…

Read More

Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models

06/22/2021

Excerpt from the Press Release: WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced new preclinical data on its IRAKIMiD degrader KT-413’s potential as both a monotherapy and in combination with other anticancer…

Read More

C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma

06/21/2021

Excerpt from the Press Release: WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, presented pre-clinical data for CFT7455, the Company’s lead program. CFT7455 is an orally bioavailable MonoDAC™ targeting IKZF1/3 for…

Read More

Nadia Chaudhri Wingspan Award supports next generation of scientific leaders at Concordia

06/18/2021

Excerpt from the Article: At the age of 43, and at the peak of her scientific career, Nadia Chaudhri received a terminal diagnosis in 2020 that altered the course of her life. “When I realized that being diagnosed with advanced ovarian cancer meant I would have to shut down my laboratory, I was devastated,” says the Department of…

Read More

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

06/18/2021

Excerpt from the Press Release: CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that the U.S. Food and Drug Administration (FDA) has cleared Cullinan Florentine’s IND application for CLN-049, a FLT3 x CD3 bispecific antibody for…

Read More

Acepodia Publishes Preclinical Data on Novel Off-the-Shelf Natural Killer Cell Therapy, ACE1702, for HER2-Expressing Solid Tumors Using Antibody-Cell Conjugation Technology in the Journal Cancers

06/18/2021

Excerpt from the Press Release: SAN MATEO, Calif., June 07, 2021 (GLOBE NEWSWIRE) — Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced that an article describing the efficacy profile of ACE1702, Acepodia’s novel, off-the-shelf natural killer (NK) cell therapy against HER2-expressing solid tumors, was published in the journal Cancers.…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives